Literature DB >> 6774362

A comparison of striatal and mesolimbic dopamine function in the rat during 6-month trifluoperazine administration.

A Clow, A Theodorou, P Jenner, C D Marsden.   

Abstract

Previous work has shown that 6---12 months continuous trifluoperazine (TFP) administration to rats causes striatal dopamine receptor supersensitivity. We have now replicated our original findings in the striatum and report concurrent changes in mesolimbic dopamine function during chronic TFP (2.8---4.0 mg/kg/day) administration for 6 months. Initial inhibition of apomorphine-induced stereotyped behaviour, which lasted for 2 weeks after the beginning of drug administration, was replaced by an exaggerated response to apomorphine (0.5 mg/kg SC) after 6 months drug intake. Striatal dopamine sensitive adenylate cyclase activity was inhibited at 1 and 3 months, but y 6 months was enhanced compared to control values. Mesolimbic adenylate cyclase activity was inhibited after 2 weeks and thereafter returned to control levels. Dopamine-identified 3H-spiperone binding sites (Bmax) in the striatum were increased by 2 weeks, reduced at 1 month and increased again at 6 months. In mesolimbic areas Bmax was increased at 2 weeks and 1 month but thereafter returned to control levels. The dissociation constant (kD) of specific 3H-spiperone binding was increased in the striatum and mesolimbic areas at 1 month and 2 weeks respectively. The results show differential changes in dopamine function in striatal and mesolimbic brain areas during 6 months continuous TFP administration to rats.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6774362     DOI: 10.1007/bf00433087

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  22 in total

1.  IS IT POSSIBLE TO PREDICT THE CLINICAL EFFECTS OF NEUROLEPTIC DRUGS (MAJOR TRANQUILLIZERS) FROM ANIMAL DATA?I. "NEUROLEPTIC ACTIVITY SPECTRA" FOR RATS.

Authors:  P A JANSSEN; C J NIEMEGEERS; K H SCHELLEKENS
Journal:  Arzneimittelforschung       Date:  1965-02

2.  Brain neurotransmitter receptors after long-term haloperidol: dopamine, acetylcholine, serotonin, alpha-noradrenergic and naloxone receptors.

Authors:  P Muller; P Seeman
Journal:  Life Sci       Date:  1977-12-15       Impact factor: 5.037

3.  Spiperone: a ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding.

Authors:  J E Leysen; W Gommeren; P M Laduron
Journal:  Biochem Pharmacol       Date:  1978-02-01       Impact factor: 5.858

4.  Tolerance phenomena with neuroleptics catalepsy, apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol.

Authors:  H Asper; M Baggiolini; H R Burki; H Lauener; W Ruch; G Stille
Journal:  Eur J Pharmacol       Date:  1973-06       Impact factor: 4.432

5.  Serotonergic component of neuroleptic receptors.

Authors:  J E Leysen; C J Niemegeers; J P Tollenaere; P M Laduron
Journal:  Nature       Date:  1978-03-09       Impact factor: 49.962

6.  Stereotyped behaviour patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nuclei.

Authors:  B Castall; C D Marsden; R J Naylor; C J Pycock
Journal:  Brain Res       Date:  1977-03-04       Impact factor: 3.252

7.  Changes in dopamine-mediated behaviour during one year's neuroleptic administration.

Authors:  A Clow; P Jenner; C D Marsden
Journal:  Eur J Pharmacol       Date:  1979-08-15       Impact factor: 4.432

8.  Clozapine: reduction of the initial dopamine turnover increase by repeated treatment.

Authors:  P C Waldmeier; L Maître
Journal:  Eur J Pharmacol       Date:  1976-07       Impact factor: 4.432

9.  Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine.

Authors:  A C Sayers; H R Bürki; W Ruch; H Asper
Journal:  Psychopharmacologia       Date:  1975

10.  Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration.

Authors:  A Clow; A Theodorou; P Jenner; C D Marsden
Journal:  Eur J Pharmacol       Date:  1980-05-02       Impact factor: 4.432

View more
  7 in total

1.  Behavioral evidence of depolarization block of dopamine neurons after chronic treatment with haloperidol and clozapine.

Authors:  S M Boye; P P Rompré
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

2.  Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride.

Authors:  E S Prosser; R Pruthi; J G Csernansky
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs.

Authors:  N M Rupniak; M D Hall; E Kelly; S Fleminger; G Kilpatrick; P Jenner; C D Marsden
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

4.  Oral dyskinesia in rats following brain lesions and neuroleptic drug administration.

Authors:  L M Gunne; J Growdon; B Glaeser
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

5.  Chronic treatments with zotepine, thioridazine, and haloperidol affect apomorphine-elicited stereotypic behavior and striatal 3H-spiroperidol binding sites in the rat.

Authors:  H Lai; M A Carino; A Horita
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

6.  Effects of discontinuous drug administration on the development of dopamine receptor supersensitivity during chronic trifluoperazine or cis-flupenthixol administration to rats.

Authors:  K Murugaiah; A Theodorou; A Clow; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

7.  Perinatal Treatments with the Dopamine D₂-Receptor Agonist Quinpirole Produces Permanent D₂-Receptor Supersensitization: a Model of Schizophrenia.

Authors:  Richard M Kostrzewa; Przemysław Nowak; Ryszard Brus; Russell W Brown
Journal:  Neurochem Res       Date:  2015-11-07       Impact factor: 3.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.